A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

NCT07481357 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric (Stomach) Cancer
GastroEsophageal Cancer
Pancreatic Ductal Adenocarcinoma (mPDAC)

Interventions

DRUG: DA-3501

Sponsor

Dong-A ST Co., Ltd.